Calcified Tissue International

, Volume 82, Issue 3, pp 182–190 | Cite as

Glucocorticoid Excess Affects Cortical Bone Geometry in Premenopausal, but not Postmenopausal, Women

  • Hiroshi Kaji
  • Mika Yamauchi
  • Kazuo Chihara
  • Toshitsugu Sugimoto
Article

Abstract

Glucocorticoid (GC) excess causes a great increase in fracture risk, but the effects of GC excess on cortical bone geometry are unknown. The present study was performed to examine the effects of GC excess on cortical bone geometry in both premenopausal and postmenopausal women. Ninety-six women receiving oral GC treatments and 10 women with Cushing syndrome (CS) were each compared to age-matched control subjects using peripheral quantitative computed tomography. Total area, periosteal circumference, and polar strength strain index (SSIp) were significantly lower in GC-treated patients compared with control subjects in premenopausal women but not in postmenopausal women. Moreover, cortical area and thickness as well as periosteal circumference and SSIp were significantly lower in patients with CS compared to controls in premenopausal women but not in postmenopausal women. Total area, cortical area, cortical thickness, periosteal circumference, as well as SSIp were significantly lower in GC-treated patients with vertebral fractures compared to those without vertebral fractures in premenopausal women but not in postmenopausal women. In conclusion, endogenous or exogenous GC excess affects bone geometry of forearms of premenopausal, but not postmenopausal, women. These effects of GC excess on bone geometry may provide a strength loss mechanism beneath increased vertebral fracture risk.

Keywords

Glucocorticoid Cushing syndrome Fracture Bone geometry 

References

  1. 1.
    Sambrook P, Birmingham J, Kempler S, Kelly P, Eberl S, Pecock N, Yeates M, Eisman J (1990) Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5:1211–1216PubMedGoogle Scholar
  2. 2.
    Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229PubMedCrossRefGoogle Scholar
  3. 3.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRefGoogle Scholar
  4. 4.
    Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323–328PubMedCrossRefGoogle Scholar
  5. 5.
    Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787PubMedCrossRefGoogle Scholar
  6. 6.
    Kanis JA, Johansson H, Oden AM, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HAP, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899PubMedCrossRefGoogle Scholar
  7. 7.
    Manelli F, Giustina A (2000) Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 11:79–85PubMedCrossRefGoogle Scholar
  8. 8.
    Kaltsas G, Manetti L, Grossman AB (2002) Osteoporosis in Cushing’s syndrome. Front Horm Res 30:60–72PubMedGoogle Scholar
  9. 9.
    Manning PJ, Evans MC, Reid IR (1992) Normal bone mineral density following cure of Cushing’s syndrome. Clin Endocrinol 36:229–234CrossRefGoogle Scholar
  10. 10.
    Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80:2859–2865PubMedCrossRefGoogle Scholar
  11. 11.
    Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing’s syndrome and bone. Pituitary 7:243–246CrossRefGoogle Scholar
  12. 12.
    Francucci CM, Pantanetti P, Garrapa GG, Massi F, Arnaldi G, Mantero F (2002) Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma. Clin Endocrinol 57:587–593CrossRefGoogle Scholar
  13. 13.
    Vestergaard P, Lindholm J, Jorgensen JOL, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen LO, Feldt-Rasmussen U, Mosekilde L (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146:51–56PubMedCrossRefGoogle Scholar
  14. 14.
    Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research. J Bone Miner Metab 23:105–109PubMedCrossRefGoogle Scholar
  15. 15.
    Kaji H, Yamauchi M, Chihara K, Sugimoto T (2006) The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 53:27–34PubMedCrossRefGoogle Scholar
  16. 16.
    NIH Consensus Development Panel on Osteoporosis Prevention. Osteoporosis prevention, diagnosis, and the therapy. JAMA 285:785–795Google Scholar
  17. 17.
    Lehmann R, Wapniarz M, Kvasnicka HM, Baedeker S, Klein K, Allolio B (1992) Reproducibility of bone density measurements of the distal radius using a high resolution special scanner for peripheral quantitative computed tomography (Single Energy PQCT). Radiology 32:177–181Google Scholar
  18. 18.
    Martin RB (1991) Determinants of the mechanical properties of bones. J Biomech 24(Suppl 1):79–88CrossRefGoogle Scholar
  19. 19.
    Smith RW Jr, Walker RR (1964) Femoral expansion in aging women: implications for osteoporosis and fractures. Science 145:156–157PubMedCrossRefGoogle Scholar
  20. 20.
    Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334PubMedCrossRefGoogle Scholar
  21. 21.
    Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K (2003) Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 88:4655–4658PubMedCrossRefGoogle Scholar
  22. 22.
    Kaji H, Kosaka R, Yamauchi M, Kuno K, Chihara K, Sugimoto T (2005) Effects of age, grip strength and smoking on forearm volumetric bone mineral density and bone geometry by peripheral quantitative computed tomography: comparisons between female and male. Endocr J 52:659–666PubMedCrossRefGoogle Scholar
  23. 23.
    Riggs BL, Melton LJ III, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, Rouleau PA, McCollough CH, Bouxsein ML, Khosla S (2004) Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 19:1945–1954PubMedCrossRefGoogle Scholar
  24. 24.
    Tsugeno H, Fujita T, Goto B, Sugishita T, Hosaki Y, Ashida K, Mitsunobu F, Tanizaki Y, Shiratori Y (2002) Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis. Osteoporos Int 13:650–656PubMedCrossRefGoogle Scholar
  25. 25.
    Lian KC, Lang TF, Keyak JH, Modin GW, Rehman Q, Do L, Lane NE (2005) Differences in hip quantitative computed tomography (QCT) measurement on bone mineral density and bone strength between glucocorticoid-treated and glucocortiocid-naïve postmenopausal women. Osteoporos Int 16:642–650PubMedCrossRefGoogle Scholar
  26. 26.
    Smith-Bindman R, Cummings SR, Steiger P, Genant HK (1991) A comparison of morphometric definitions of vertebral fractures. J Bone Miner Res 6:25–34PubMedCrossRefGoogle Scholar
  27. 27.
    Ruegsegger P, Durand E, Dambacher MA (1991) Localization of regional forearm bone loss from high-resolution computed tomographic images. Osteoporos Int 1:76–80PubMedCrossRefGoogle Scholar
  28. 28.
    Schiessl H, Ferretti JL, Tysarczyk-Niemeyer G (1996) Noninvasive bone strength index as analysis by peripheral quantitative computed tomography (pQCT). In: Schonau E (ed) Pediatric osteology. New developments in diagnostics and therapy. Elsevier, Amsterdam, pp 147–160Google Scholar
  29. 29.
    Ashizawa N, Nonaka K, Michikami S, Mizuki T, Amagai H, Tokuyama K, Suzuki M (1999) Tomographical description of tennis-loaded radius: reciprocal relation between bone size and volumetric BMD. J Appl Phys 86:1347–1351Google Scholar
  30. 30.
    Ørtoft G, Oxlund H (1996) Qualitative alterations of cortical bone in female rats after long-term administration of growth hormone and glucocorticoid. Bone 18:581–590PubMedCrossRefGoogle Scholar
  31. 31.
    Ikeda S, Morishita Y, Tsutsumi H, Ito M, Shiraishi A, Arita S, Asahoshi S, Narusawa K, Nakamura T (2003) Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs. Bone 33:779–787PubMedCrossRefGoogle Scholar
  32. 32.
    Kaji H, Tobimatsu T, Naito J, Iu MF, Yamauchi M, Sugimoto T, Chihara K (2006) Body composition and vertebral fracture risk in female patients treated with glucocorticoid. Osteoporos Int 17:627–633PubMedCrossRefGoogle Scholar
  33. 33.
    Michel BA, Bloch DA, Wolfe F, Fries JF (1993) Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 20:1666–1669PubMedGoogle Scholar
  34. 34.
    Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop P, Rairie JE, Fitzgerald S, Manzi S (1999) Frequency for fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42:882–890PubMedCrossRefGoogle Scholar
  35. 35.
    Faggiano A, Pivonello R, Filippella M, Di Somma C, Orio F Jr, Lombard G, Colao A (2001) Spine abnormalities and damage in patients cured from Cushing’s disease. Pituitary 4:153–161PubMedCrossRefGoogle Scholar
  36. 36.
    Chiodini I, Carnevale V, Torlontano M, Fusilli S, Guglielmi G, Peleri M, Modoni S, Di Giorgio A, Liuzzi A, Minisola S, Cammisa M, Trischotta V, Scillitani A (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing’s syndrome. J Clin Endocrinol Metab 83:1863–1867PubMedCrossRefGoogle Scholar
  37. 37.
    Rubin MR, Bilezikian JP (2002) The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87:4033–4041PubMedCrossRefGoogle Scholar
  38. 38.
    Unsi-Rasi K, Semanick IM, Zanchetta JR, Bogado CZ, Eriksen EF, Sato M, Beck IJ (2005) Effects of teriparatide [rhPTH(1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958CrossRefGoogle Scholar
  39. 39.
    Ferretti JL, Capozza RF, Mondelo N, Zanchetta JR (1993) Interrelationships between densitometric, geometric, and mechanical properties of rat femora: inferences concerning mechanical regulation of bone modeling. J Bone Miner Res 8:1389–1396PubMedGoogle Scholar
  40. 40.
    Myers ER, Hecker AT, Rooks DS, Hipp JA, Hayes WC (1993) Geometric variables from DXA of the radius predict forearm fracture load in vitro. Calcif Tissue Int 52:199–204PubMedCrossRefGoogle Scholar
  41. 41.
    Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15:1368–1375PubMedCrossRefGoogle Scholar
  42. 42.
    Yamauchi M, Sugimoto T, Chihara K (2004) Determinants of vertebral fragility: the participation of cortical bone factors. J Bone Miner Metab 22:79–85PubMedCrossRefGoogle Scholar
  43. 43.
    Karavitaki N, Ioannidis G, Giannakopoulos F, Marvrokefalos P, Thalassinos N (2004) Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing’s syndrome. Clin Endocrinol 60:264–270CrossRefGoogle Scholar
  44. 44.
    Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, Lombardi G, Colao A (2003) Effect of 2 years of cortisol normalization on the impared bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin Endocrinol 58:302–308CrossRefGoogle Scholar
  45. 45.
    Di Somma C, Pivonello R, Loche S, Faggiano A, Marzullo P, Di Sarno A, Klain M, Salvatore M, Lombardi G, Colao A (2002) Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol 56:153–158CrossRefGoogle Scholar
  46. 46.
    Ruegsegger P, Medici T, Anliker M (1983) Corticosteroid-induced bone loss: a longitudinal study of alternate therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Parmacol 25:615–620CrossRefGoogle Scholar
  47. 47.
    Seeman E (1997) From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res 12:509–521PubMedCrossRefGoogle Scholar
  48. 48.
    Russo CR, Lauretani F, Bandinelli S, Bartali B, Di Iorio A, Volpato S, Guralnik JM, Harris T, Ferrucci L (2003) Aging bone in men and women: beyond changes in bone mineral density. Osteoporos Int 14:531–538PubMedCrossRefGoogle Scholar
  49. 49.
    Vanderschueren D, Venken K, Ophoff J, Bouillon R, Boonen S (2006) Sex steroids and the periosteum—reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endcocrinol Metab 91:378–382CrossRefGoogle Scholar
  50. 50.
    Saxon LK, Turner CH (2006) Low-dose estrogen treatment suppresses periosteal bone formation in response to mechanical loading. Bone 39:1261–1267PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Hiroshi Kaji
    • 1
  • Mika Yamauchi
    • 2
  • Kazuo Chihara
    • 1
  • Toshitsugu Sugimoto
    • 2
  1. 1.Division of Diabetes, Metabolism, and Endocrinology, Department of Internal MedicineKobe University Graduate School of MedicineKobeJapan
  2. 2.Internal Medicine 1Shimane University Faculty of MedicineIzumoJapan

Personalised recommendations